XBiotech Announces New Patents for Third Quarter 2018
Patents Granted/Allowed for Company’s Candidate Treatments for Cardiovascular Disease, Staphylococcus Aureus Infections and its Antibody Discovery Technology
AUSTIN, Texas, Oct. 26, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it was awarded 11 new patents or patent allowances in the third quarter of 2018. Patents issued relate to the Company’s drug candidates bermekimab and 514G3, which target a crucial mediator of chronic inflammation and Staphylococcus aureus (including MRSA), respectively. The new patents include those issued from European authorities to protect bermekimab when used in the treatment of dermatological pathologies and cancer-associated cachexia. Patent allowances include one each in Australia, Canada, Israel, Mexico, the Philippines, Russia, and South Korea that include covering: bermekimab in the treatment of cardiovascular disease; the 514G3 antibody to treat Staphylococcus aureus infections; and key aspects of the Company’s True HumanTM antibody discovery platform.
Stanley Kim, Ph.D., J.D., XBiotech’s Corporate Vice President of Intellectual Property, stated, “These recently issued patents reflect XBiotech’s efforts to develop significant worldwide protection for its emerging candidate therapies. The Company’s patent portfolio currently includes over 100 issued patents.”
XBiotech’s substantial patent portfolio supports a diverse drug development platform. The Company is currently conducting clinical research with bermekimab as a combination therapy to treat pancreatic cancer. In addition, ongoing evaluation of results from XBiotech’s colorectal cancer programs continues to be conducted to investigate patient response to bermekimab and to further direct the Company’s oncology program. XBiotech has two separate dermatological clinical trials underway investigating response to bermekimab in patients with atopic dermatitis and hidradenitis suppurativa. Both studies are expected to be completed this year or by first quarter 2019. The Company is also currently exploring possibilities of conducting further clinical studies with 514G3 to prevent and treat Staphylococcus aureus infections, as well as bermekimab to prevent and treat cardiovascular disease. XBiotech continues to advance its pipeline for other infectious disease indications, including Clostridium difficile and varicella zoster virus (shingles).
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Continued Growth for INVNT Following Client Wins, An Expanded Offering, New Offices and Fresh Talent23.4.2019 15:20:00 CEST | Pressemelding
NEW YORK, NY, April 23, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, achieved a number of milestones in 2018, a move that saw its revenues reach over $54 million, exceeding forecasts and representing a 30% increase on the previous year. With a number of impressive new clients and continued expansion in the works, the agency is targeting $62 million in revenue for 2019. INVNT secured new clients including Microsoft, Facebook, Pfizer, Xero, TEDxSydney, New Relic and Mary Kay last year. They grew many accounts from local to global, a move that now sees INVNTrs deliver campaigns for clients across the globe. INVNT also exceeded existing clients’ expectations in 2018, delivering compelling live brand storytelling™ moments for the likes of General Motors, Grant Thornton, Merck, PepsiCo, Samsung and Subway. Scott Cullather, CEO, INVNT explains: “Our tremendous growth is due to a combination of our team’s ability to develop compelling live brand stories that are
Always Powered by Passion: Meizu 16s Flagship Smartphone Unveiled, Snapdragon 855 and 48MP OIS Dual Camera23.4.2019 15:00:00 CEST | Pressemelding
Zhuhai, April 23, 2019 (GLOBE NEWSWIRE) -- Zhuhai, 23rd April 2019 -- Meizu Technology Co., Ltd (Meizu) has officially introduced its latest flagship 16s and will be available for sale in China on 28th April starting at 3198 RMB. The signature Meizu Design brings a sense of elegance to the phone. Powered by Qualcomm Snapdragon 855, the 16s features a 48MP + OIS Dual Camera, making it the best device to use for everyday shots. The latest flagship 16s is a testament to the 16 years’ experience in phone making of Meizu. The company has spared no effort with 100% dedication in producing premium phone for quality-seeking users, despite the size of the target market. 16s is a product that reflects ‘100% efforts for 1% selected Products’, Meizu strives for excellence with passion. Meizu 16s comes in Pearl White, Carbon Black, and Phantom Blue, of which 6+128G, 8+128G and 8+256G will be respectively priced at 3198 RMB, 3498 RMB and 3998 RMB, and will be available on Meizu official website for
iGrafx Announces Cohesive RPA Accelerator Solution23.4.2019 14:48:00 CEST | Pressemelding
Combines Core Capabilities from iGrafx, myInvenio, Servicetrace, UiPath and BP3 Global Dallas, TX, April 23, 2019 (GLOBE NEWSWIRE) -- Today at the iNNOVATE 2019 conference, iGrafx unveiled the industry’s first end-to-end RPA Accelerator solution, enabling enterprises to identify, assess, prioritize, execute and govern robotic process automation (RPA) projects. The turnkey package includes a new version of the iGrafx Platform, along with process mining from myInvenio, RPA bots from either UiPath or Servicetrace and professional services from BP3. For the first time ever, Center of Excellence leaders can access the combined, best-of-breed capabilities from a single source for a single price. “Our customers tell us that they have a huge challenge understanding what to optimize and automate in order to achieve real digital transformation,” said Ryan Tognazzini, CEO at iGrafx. This is a challenge that is also iterated again and again by industry experts. In a recent Forrester report, Rob Ko
MJBizDaily Introduces MJBizDaily European Cannabis Symposium, Copenhagen, Denmark, May 623.4.2019 11:00:00 CEST | Pressemelding
DENVER, April 23, 2019 (GLOBE NEWSWIRE) -- The producers of America’s oldest and largest cannabis trade show, Marijuana Business Conference & Expo (MJBizCon), introduce MJBizDaily’s European Cannabis Symposium in Denmark, Copenhagen. MJBizDaily’s European Cannabis Symposium will take place on Monday, May 6 at the Scandic Copenhagen Hotel in Copenhagen, Denmark. Leaders in the business, research and legislation of Europe’s medical marijuana and hemp market will gather for an intensive one-day conference offering educational sessions on the latest in tech, scientific research, and potential impacts on global markets. Table top exhibitors and an opening cocktail reception on Sunday, May 5 will also offer invaluable networking opportunities. “Regulated, normalized cannabis programs are just now starting to come into their own across Europe. As those government, industry and scientific ties continue to strengthen across the continent, the time is right to provide an in-person platform for e
LeddarTech Appoints Richard LaRue, a Seasoned Corporate International Lawyer, to its Executive Team23.4.2019 06:58:00 CEST | Pressemelding
LeddarTech Increases Automotive LiDAR Expertise with a Research and Development Team in Toronto, Canada LeddarTech enhances its senior management leadership team through the appointment of a Chief Legal Officer and further accelerates time to market by announcing the official opening of the Automotive Center of Excellence R&D facility in Toronto, Canada. QUEBEC CITY, April 23, 2019 (GLOBE NEWSWIRE) -- LeddarTech®, an industry leader providing the most versatile and scalable auto and mobility LiDAR platform ™, is pleased to announce the appointment of Mr. Richard LaRue as Chief Legal Officer. Mr. LaRue has worked extensively with software and biotech companies, as well as start-ups, in all aspects of their business, including their constitution, the negotiation, and drafting of international agreements and their equity and debt financing. He has practiced in these areas across Canada, Europe, and the U.S. “I look forward to leveraging my international experience in corporate law, financ
WillScot to Announce First Quarter 2019 Results on May 2, 201922.4.2019 22:04:00 CEST | Pressemelding
BALTIMORE, April 22, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (NASDAQ: WSC) today announced that it will release its first quarter 2019 financial results on Thursday, May 2, 2019 after the markets close. President and Chief Executive Officer, Bradley Soultz, and Chief Financial Officer, Timothy Boswell will host a conference call and webcast on Friday, May 3, 2019 at 10:00 a.m. EDT to discuss the results. The live call can be accessed by dialing (855) 312-9420 (US/Canada toll-free) or (210) 874-7774 (International). A live webcast will also be accessible via the “Events & Presentations” section of the Company’s Investor Relations website https://investors.willscot.com. An archived version of the webcast will be available for 60 days following the call. About WillScot Corporation Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corpora